134 related articles for article (PubMed ID: 33007547)
1. Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase.
Shaw SA; Vokits BP; Dilger AK; Viet A; Clark CG; Abell LM; Locke GA; Duke G; Kopcho LM; Dongre A; Gao J; Krishnakumar A; Jusuf S; Khan J; Spronk SA; Basso MD; Zhao L; Cantor GH; Onorato JM; Wexler RR; Duclos F; Kick EK
Bioorg Med Chem; 2020 Nov; 28(22):115723. PubMed ID: 33007547
[TBL] [Abstract][Full Text] [Related]
2. Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO).
Hu CH; Neissel Valente MW; Halpern OS; Jusuf S; Khan JA; Locke GA; Duke GJ; Liu X; Duclos FJ; Wexler RR; Kick EK; Smallheer JM
Bioorg Med Chem Lett; 2021 Jun; 42():128010. PubMed ID: 33811992
[TBL] [Abstract][Full Text] [Related]
3. Generation of 3,8-substituted 1,2,4-triazolopyridines as potent inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1).
Wang H; Robl JA; Hamann LG; Simpkins L; Golla R; Li YX; Seethala R; Zvyaga T; Gordon DA; Li JJ
Bioorg Med Chem Lett; 2011 Jul; 21(14):4146-9. PubMed ID: 21689935
[TBL] [Abstract][Full Text] [Related]
4. Triazolopyrimidine and triazolopyridine scaffolds as TDP2 inhibitors.
Ribeiro CJA; Kankanala J; Xie J; Williams J; Aihara H; Wang Z
Bioorg Med Chem Lett; 2019 Jan; 29(2):257-261. PubMed ID: 30522956
[TBL] [Abstract][Full Text] [Related]
5. Novel bis-arylalkylamines as myeloperoxidase inhibitors: Design, synthesis, and structure-activity relationship study.
Aldib I; Gelbcke M; Soubhye J; Prévost M; Furtmüller PG; Obinger C; Elfving B; Alard IC; Roos G; Delporte C; Berger G; Dufour D; Zouaoui Boudjeltia K; Nève J; Dufrasne F; Van Antwerpen P
Eur J Med Chem; 2016 Nov; 123():746-762. PubMed ID: 27537923
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Guaiacol Derivatives as Promising Myeloperoxidase Inhibitors Targeting Atherosclerotic Cardiovascular Disease.
Premkumar J; Sampath P; Sanjay R; Chandrakala A; Rajagopal D
ChemMedChem; 2020 Jul; 15(13):1187-1199. PubMed ID: 32368837
[TBL] [Abstract][Full Text] [Related]
7. The development of myeloperoxidase inhibitors.
Galijasevic S
Bioorg Med Chem Lett; 2019 Jan; 29(1):1-7. PubMed ID: 30466896
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel indole pharmacophore for the irreversible inhibition of myeloperoxidase (MPO).
Patnaik A; Axford L; Deng L; Cohick E; Ren X; Loi S; Kecman S; Hollis-Symynkywicz M; Harrison TJ; Papillon JPN; Dales N; Hamann LG; Lee L; Regard JB; Marcinkeviciene J; Marro ML; Patterson AW
Bioorg Med Chem; 2020 Jun; 28(12):115548. PubMed ID: 32503688
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases.
Ruggeri RB; Buckbinder L; Bagley SW; Carpino PA; Conn EL; Dowling MS; Fernando DP; Jiao W; Kung DW; Orr ST; Qi Y; Rocke BN; Smith A; Warmus JS; Zhang Y; Bowles D; Widlicka DW; Eng H; Ryder T; Sharma R; Wolford A; Okerberg C; Walters K; Maurer TS; Zhang Y; Bonin PD; Spath SN; Xing G; Hepworth D; Ahn K; Kalgutkar AS
J Med Chem; 2015 Nov; 58(21):8513-28. PubMed ID: 26509551
[TBL] [Abstract][Full Text] [Related]
10. Characterization of chemical features of potent myeloperoxidase inhibitors.
Soubhye J; Meyer F; Furtmüller P; Obinger C; Dufrasne F; Antwerpen PV
Future Med Chem; 2016 Jul; 8(11):1163-77. PubMed ID: 27402298
[TBL] [Abstract][Full Text] [Related]
11. Methoxyphenol derivatives as reversible inhibitors of myeloperoxidase as potential antiatherosclerotic agents.
Jayaraj P; Narasimhulu CA; Maiseyeu A; Durairaj R; Rao S; Rajagopalan S; Parthasarathy S; Desikan R
Future Med Chem; 2020 Jan; 12(2):95-110. PubMed ID: 31769316
[No Abstract] [Full Text] [Related]
12. Mapping myeloperoxidase to identify its promiscuity properties using docking and molecular dynamics simulations.
Ramírez-Durán LA; Rosales-Hernández MC; Hernández-Rodríguez M; Mendieta-Wejebe JE; Trujillo-Ferrara J; Correa-Basurto J
Curr Pharm Des; 2013; 19(12):2204-15. PubMed ID: 23016839
[TBL] [Abstract][Full Text] [Related]
13. Flavonoids as substrates and inhibitors of myeloperoxidase: molecular actions of aglycone and metabolites.
Shiba Y; Kinoshita T; Chuman H; Taketani Y; Takeda E; Kato Y; Naito M; Kawabata K; Ishisaka A; Terao J; Kawai Y
Chem Res Toxicol; 2008 Aug; 21(8):1600-9. PubMed ID: 18620432
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Myeloperoxidase.
Soubhye J; Furtmüller PG; Dufrasne F; Obinger C
Handb Exp Pharmacol; 2021; 264():261-285. PubMed ID: 33372235
[TBL] [Abstract][Full Text] [Related]
15. Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates.
Forbes LV; Sjögren T; Auchère F; Jenkins DW; Thong B; Laughton D; Hemsley P; Pairaudeau G; Turner R; Eriksson H; Unitt JF; Kettle AJ
J Biol Chem; 2013 Dec; 288(51):36636-47. PubMed ID: 24194519
[TBL] [Abstract][Full Text] [Related]
16. The soluble curcumin derivative NDS27 inhibits superoxide anion production by neutrophils and acts as substrate and reversible inhibitor of myeloperoxidase.
Franck T; Aldib I; Zouaoui Boudjeltia K; Furtmüller PG; Obinger C; Neven P; Prévost M; Soubhye J; Van Antwerpen P; Mouithys-Mickalad A; Serteyn D
Chem Biol Interact; 2019 Jan; 297():34-43. PubMed ID: 30342014
[TBL] [Abstract][Full Text] [Related]
17. Myeloperoxidase as a Target for the Treatment of Inflammatory Syndromes: Mechanisms and Structure Activity Relationships of Inhibitors.
Soubhye J; Aldib I; Delporte C; Prévost M; Dufrasne F; Antwerpen PV
Curr Med Chem; 2016; 23(35):3975-4008. PubMed ID: 27281130
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
Soubhye J; Chikh Alard I; Aldib I; Prévost M; Gelbcke M; De Carvalho A; Furtmüller PG; Obinger C; Flemmig J; Tadrent S; Meyer F; Rousseau A; Nève J; Mathieu V; Zouaoui Boudjeltia K; Dufrasne F; Van Antwerpen P
J Med Chem; 2017 Aug; 60(15):6563-6586. PubMed ID: 28671460
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic characterization of a 2-thioxanthine myeloperoxidase inhibitor and selectivity assessment utilizing click chemistry--activity-based protein profiling.
Ward J; Spath SN; Pabst B; Carpino PA; Ruggeri RB; Xing G; Speers AE; Cravatt BF; Ahn K
Biochemistry; 2013 Dec; 52(51):9187-201. PubMed ID: 24320749
[TBL] [Abstract][Full Text] [Related]
20. Conception of myeloperoxidase inhibitors derived from flufenamic acid by computational docking and structure modification.
Van Antwerpen P; Prévost M; Zouaoui-Boudjeltia K; Babar S; Legssyer I; Moreau P; Moguilevsky N; Vanhaeverbeek M; Ducobu J; Nève J; Dufrasne F
Bioorg Med Chem; 2008 Feb; 16(4):1702-20. PubMed ID: 18063373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
